GBT Guerbet SA

GUERBET : Financial agenda for 2025

GUERBET : Financial agenda for 2025

Financial agenda for 2025

Villepinte, 31 October 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025.

Publications calendar
  • 2024 ANNUAL REVENUE
February 06, 2025, after trading
  • 2024 ANNUAL RESULTS
March 27, 2025, after trading
  • 2025 1st QUARTER REVENUE
April 24, 2025, after trading
  • ANNUAL SHAREHOLDERS’ MEETING
May 23, 2025
  • 2025 2nd QUARTER REVENUE
July 24, 2025, after trading
  • 2025 FIRST HALF RESULTS
September 25, 2025, after trading
  • 2025 3rd QUARTER REVENUE
October 23, 2025, after trading

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, in United States and Israël. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €786 million in revenue in 2023.





Contacts:

Guerbet     

Jérôme Estampes, Chief Financial Officer 00 /  

Christine Allard, Head of Public Affairs and Communications: 82 /

Seitosei.Actifin                                                                                       

Marianne Py, Financial Communication 31 /

Jennifer Jullia, Press 19 /

Attachment



EN
31/10/2024

Underlying

GBTGuerbet SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Guerbet SA

Anthony Dick ... (+3)
  • Anthony Dick
  • Emira Sagaama
  • Michael Foundoukidis
NDX1 NORDEX SE
VAC PIERRE & VACANCES SA
NXI NEXITY SA CLASS A
MF WENDEL SE
EXE EXEL INDUSTRIES SA
BIO BB BIOTECH AG
BLC BASTIDE LE CONFORT MEDICAL SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
MRN MERSEN SA
FII LISI SA
GBT GUERBET SA
ATE ALTEN SA
FR VALEO SE
XIOR XIOR STUDENT HOUSING N.V.
MIL BANK MILLENNIUM SA
SAVE SAVENCIA SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
TIETO TIETOEVRY OYJ
VIS VISCOFAN S.A.
CCC CCC SA
AALB AALBERTS N.V.
CARM CARMILA SAS
LIGHT SIGNIFY NV
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
BRAV BRAVIDA HOLDING AB
LFDE LA FRANCAISE DE L'ENERGIE SA
HOME NEINOR HOMES SA
MDM MAISONS DU MONDE SA
SMCP SMCP SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
TMV TEAMVIEWER AG
ZGN ERMENEGILDO ZEGNA NV
SPM SAIPEM S.P.A.
AROBS AROBS TRANSILVANIA SOFTWARE SA
R3NK RENK GROUP AG
PLNW PLANISWARE
4X0 STEYR MOTORS AG
LOCAL SOLOCAL GROUP
10/24/25 October 24, 2025 1 EN
Anthony Dick ... (+3)
  • Anthony Dick
  • Emira Sagaama
  • Michael Foundoukidis
NDX1 NORDEX SE
VAC PIERRE & VACANCES SA
NXI NEXITY SA CLASS A
MF WENDEL SE
EXE EXEL INDUSTRIES SA
BIO BB BIOTECH AG
BLC BASTIDE LE CONFORT MEDICAL SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
MRN MERSEN SA
FII LISI SA
GBT GUERBET SA
ATE ALTEN SA
FR VALEO SE
XIOR XIOR STUDENT HOUSING N.V.
MIL BANK MILLENNIUM SA
SAVE SAVENCIA SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
TIETO TIETOEVRY OYJ
VIS VISCOFAN S.A.
CCC CCC SA
AALB AALBERTS N.V.
CARM CARMILA SAS
LIGHT SIGNIFY NV
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
LFDE LA FRANCAISE DE L'ENERGIE SA
HOME NEINOR HOMES SA
MDM MAISONS DU MONDE SA
SMCP SMCP SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
TMV TEAMVIEWER AG
ZGN ERMENEGILDO ZEGNA NV
SPM SAIPEM S.P.A.
AROBS AROBS TRANSILVANIA SOFTWARE SA
R3NK RENK GROUP AG
PLNW PLANISWARE
4X0 STEYR MOTORS AG
LOCAL SOLOCAL GROUP
10/24/25 October 24, 2025 1 FR
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
10/24/25 October 24, 2025 1 EN
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
10/24/25 October 24, 2025 1 FR
 PRESS RELEASE
Free
GBT GUERBET SA

Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croiss...

Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3ème trimestre 2025. Confirmation de l’ensemble des objectifs financiers 2025. Chiffre d’affaires au 30 septembre 2025 Retour de la croissance au 3ème trimestre 2025 Chiffre d’affaires à 9 mois : 586,5 M€, en retrait de 2,8% à TCC1 et périmètre comparable2, largement dû à la baisse de l’activité en France        Au troisième trimestre, une hausse de 2,6% à TCC et périmètre comparable, soutenue par l’accélération des ventes d’EluciremTM et la dynamique sur Lipiodol® Confirmation de l’ensemble des objectifs fina...

October 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch